Table 3 Basic patient and tumor characteristics in cases included and not included in the analysis
Entire HE10/00 cohort: 1,086 patients | Included (N = 663) | Not included (N = 423) | p value |
|---|---|---|---|
N (%) | N (%) | ||
Adjuvant hormonal therapy | |||
Yes | 486 (75.8) | 293 (73.3) | 0.35 |
No | 155 (24.2) | 107 (26.7) | |
Adjuvant radiotherapy | |||
Yes | 480 (75.6) | 296 (73.8) | 0.52 |
No | 155 (24.4) | 105 (26.2) | |
Age | |||
<50 | 240 (36.2) | 195 (46.2) | 0.001 |
≥50 | 423 (63.8) | 227 (53.8) | |
EGFR protein expression | |||
Positive | 96 (15.2) | 22 (17.5) | 0.52 |
Negative (<1%) | 537 (84.8) | 104 (82.5) | |
ER/PgR status | |||
Negative | 169 (25.5) | 116 (27.5) | 0.48 |
Positive | 493 (74.5) | 306 (72.5) | |
Histological grade | |||
I–II | 326 (49.2) | 237 (56.3) | 0.022 |
III-undifferentiated | 337 (50.8) | 184 (43.7) | |
HER2 protein expression | |||
Overexpression | 195 (30.4) | 165 (40.6) | 0.001 |
No overexpression | 446 (69.6) | 241 (59.4) | |
HER2 status (IHC/FISH) | |||
Negative | 489 (77.4) | 98 (73.1) | 0.29 |
Positive | 143 (22.6) | 36 (26.9) | |
Histological type | |||
Invasive ductal | 529 (79.7) | 323 (76.5) | 0.18 |
Invasive lobular | 64 (9.7) | 45 (10.7) | |
Mixed | 41 (6.2) | 23 (5.5) | |
Other | 29 (4.4) | 31 (7.3) | |
Interval from operation | |||
<2 weeks | 49 (7.4) | 33 (7.9) | 0.79 |
2–4 weeks | 291 (44.0) | 192 (45.7) | |
>4 weeks | 321 (48.6) | 195 (46.4) | |
Menopausal status | |||
Pre | 282 (42.5) | 220 (52.0) | 0.002 |
Post | 381 (57.5) | 203 (48.0) | |
Number of positive nodes | |||
1–3 | 302 (45.6) | 224 (53.0) | 0.017 |
≥4 | 361 (54.4) | 199 (47.0) | |
Tumor size | |||
≤2 cm | 197 (29.7) | 149 (35.5) | 0.048 |
>2 cm | 466 (70.3) | 271 (64.5) | |
Subtype classification | |||
Luminal A | 190 (30.4) | 34 (27.6) | 0.40 |
Luminal B | 217 (34.7) | 35 (28.5) | |
Luminal-HER2 | 79 (12.7) | 21 (17.1) | |
HER2-enriched | 64 (10.2) | 14 (11.4) | |
Triple-negative | 75 (12.0) | 19 (15.4) | |
Type of surgery | |||
Modified radical mastectomy | 446 (67.3) | 262 (62.1) | 0.080 |
Breast-conserving | 217 (32.7) | 160 (37.9) | |